Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. This ...

The appraisal committee has prepared final draft guidance (FDG) on durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer and submitted it to ...

Tools to help you put the guidance into practice.

Selpercatinib (Retsevmo, Eli Lilly) as monotherapy is indicated for 'the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET ...

The National Institute for Health and Care Excellence (NICE) is producing late-stage assessment guidance on Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...